Liquidia Corporation said that a new agreement will supersede its 2012 license agreement with GSK that gave GSK exclusive rights to develop certain inhaled formulations based on Liquidia’s PRINT particle engineering technology. In 2015, GSK exercised an option giving it exclusive worldwide rights to develop PRINT formulations of inhaled therapies, with the exception of treprostinil (now Yutrepia.)
Under the new agreement, Liquidia said, GSK will continue to have a non-exclusive license for pre-clinical R&D, and Liquidia will be able to use PRINT for “all inhaled formulations other than certain identified GSK proprietary molecules.” If GSK wants to advance a new inhaled PRINT formulation into the clinic, it will need to acquire an additional license.
Liquidia CEO Roger Jeffs said, “We are very happy to have re-structured our relationship with GSK to enable both parties to maximize the proven benefits of PRINT technology for inhaled delivery. As demonstrated by Yutrepia, the ability to precisely engineer uniform particles for inhalation can enhance patient benefits. This agreement will enable Liquidia to develop more products and collaborations that leverage the proprietary benefits of PRINT to deliver high-value, inhaled medicines. At the same time, GSK will be able to explore the use of PRINT for potential new therapies.”
Read the Liquidia Corporation press release.
